Active matrix metalloproteinase-8 (aMMP-8) point-of-care test (POCT) in the COVID-19 pandemic.
Timo SorsaVaibhav SahniNurcan BuduneliShipra GuptaIsmo Tapani RäisänenLorne M GolubHsi-Ming LeeTommi PätiläNagihan BostanciJukka H MeurmanPirjo PärnänenSolomon O NwhatorMohita SinglaKrishan GaubaPublished in: Expert review of proteomics (2021)
The mouthrinse aMMP-8 POCT can also detect prediabetes/diabetes and tissue destructive oral side-effects due to the head and neck cancers' radiotherapy. Chlorhexidine and doxycycline can inhibit collagenolytic human neutrophil and GCF aMMP-8. Furthermore, by a set of case-series we demonstrate the potential of mouthrinse aMMP-8 POCT to real-time/online detect periodontitis as a potential risk disease for coronavirus disease 2019 (COVID-19). The clinical interdisciplinary utilization of aMMP-8 POCT requires additional oral, medical, and interdisciplinary studies.
Keyphrases
- coronavirus disease
- endothelial cells
- type diabetes
- sars cov
- healthcare
- cardiovascular disease
- early stage
- respiratory syndrome coronavirus
- human health
- social media
- radiation therapy
- health information
- risk assessment
- pluripotent stem cells
- induced pluripotent stem cells
- young adults
- insulin resistance
- rectal cancer